US2443266A
(en)
*
|
1944-09-02 |
1948-06-15 |
Bendix Aviat Corp |
Commutator brush holder
|
US3117142A
(en)
|
1961-03-01 |
1964-01-07 |
Roussel Uclaf |
Novel preparation of estradiol and estrone
|
US3169134A
(en)
|
1963-03-21 |
1965-02-09 |
Searle & Co |
2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
|
BE754111A
(fr)
|
1969-07-29 |
1971-01-29 |
Upjohn Co |
Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
|
US3943124A
(en)
|
1970-12-17 |
1976-03-09 |
Gordon Hanley Phillipps |
Chemical compounds
|
GB1430942A
(en)
|
1972-05-05 |
1976-04-07 |
Glaxo Lab Ltd |
21-substituted 3alpha-hydroxy pregnanes
|
US3983111A
(en)
|
1972-05-05 |
1976-09-28 |
Glaxo Laboratories Limited |
Steroidal anaesthetics of the pregnane and 19-norpregnane series
|
US3865939A
(en)
|
1973-02-23 |
1975-02-11 |
Procter & Gamble |
Edible oils having hypocholesterolemic properties
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
US4192871A
(en)
|
1976-01-06 |
1980-03-11 |
Glaxo Laboratories Limited |
Chemical compounds
|
GB1570394A
(en)
|
1976-01-06 |
1980-07-02 |
Glaxo Lab Ltd |
11-acyloxy-3-hydroxy steroids
|
GB1581234A
(en)
|
1976-04-05 |
1980-12-10 |
Glaxo Operations Ltd |
11a - amino - 3a - hydroxysteroids
|
US5847009A
(en)
|
1986-01-14 |
1998-12-08 |
Alliance Pharmaceutical Corp. |
Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
|
SE8600632D0
(sv)
|
1986-02-13 |
1986-02-13 |
Kabivitrum Ab |
Novel pharmaceutical composition
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
US5120723A
(en)
|
1987-08-25 |
1992-06-09 |
University Of Southern California |
Method, compositions, and compounds for modulating brain excitability
|
US5319115A
(en)
|
1987-08-25 |
1994-06-07 |
Cocensys Inc. |
Method for making 3α-hydroxy, 3β-substituted-pregnanes
|
US5719197A
(en)
|
1988-03-04 |
1998-02-17 |
Noven Pharmaceuticals, Inc. |
Compositions and methods for topical administration of pharmaceutically active agents
|
US4938763B1
(en)
|
1988-10-03 |
1995-07-04 |
Atrix Lab Inc |
Biodegradable in-situ forming implants and method of producing the same
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
MY107937A
(en)
|
1990-02-13 |
1996-06-29 |
Takeda Chemical Industries Ltd |
Prolonged release microcapsules.
|
JPH06510999A
(ja)
|
1991-09-13 |
1994-12-08 |
コセンシス・インコーポレイテッド |
ステロイド結合部位を有する新規GABA↓aレセプター
|
US5411737A
(en)
|
1991-10-15 |
1995-05-02 |
Merck & Co., Inc. |
Slow release syneresing polymeric drug delivery device
|
DE69435286D1
(de)
|
1993-05-24 |
2010-05-20 |
Purdue Pharma Ltd |
Verfahren und zusammensetzungen zum hervorrufen von schlaf
|
EP0656365B1
(en)
|
1993-12-02 |
1997-04-09 |
Akzo Nobel N.V. |
Substituted 2beta-morpholinoandrostane derivatives
|
DE69518509T2
(de)
|
1994-02-14 |
2001-04-19 |
Euro Celtique Sa |
Androstane und pregnane zur allosterischen modulation des gaba-rezeptors
|
US5939545A
(en)
|
1994-02-14 |
1999-08-17 |
Cocensys, Inc. |
Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
|
KR100477070B1
(ko)
|
1994-03-25 |
2006-04-21 |
이소테크니카 인코포레이티드 |
중수소화작용에의한의약품의효능강화법
|
AU3125695A
(en)
|
1994-07-21 |
1996-02-22 |
Pharmacia & Upjohn Company |
Neurologically active aminosteroids
|
CZ292881B6
(cs)
|
1994-11-23 |
2003-12-17 |
Euro-Celtique S.A. |
Androstanová a pregnanová řada pro allosterickou modulaci GABA receptoru
|
US6780853B1
(en)
|
1995-06-06 |
2004-08-24 |
Euro-Celtique S.A. |
Neuroactive steroids of the androstane and pregnane series
|
WO1996040043A2
(en)
|
1995-06-06 |
1996-12-19 |
Cocensys, Inc. |
Neuroactive steroids of the androstane and pregnane series
|
EP0840612A1
(en)
|
1995-07-24 |
1998-05-13 |
Trustees Of Boston University |
Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
|
WO1998005337A1
(en)
|
1996-08-01 |
1998-02-12 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
ATE272394T1
(de)
|
1996-10-31 |
2004-08-15 |
Takeda Chemical Industries Ltd |
Zubereitung mit verzögerter freisetzung
|
US7630757B2
(en)
|
1997-01-06 |
2009-12-08 |
Flint Hills Scientific Llc |
System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
|
US6046177A
(en)
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
US5874418A
(en)
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
US6316613B1
(en)
|
1997-07-25 |
2001-11-13 |
Beckman Coulter, Inc. |
Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
|
US6245757B1
(en)
|
1997-10-03 |
2001-06-12 |
Research Corporation Technologies, Inc. |
Use of progestins to treat ischemic event
|
JP3877961B2
(ja)
*
|
1998-03-11 |
2007-02-07 |
ベクストルム,トルビエーン |
Cns疾患の治療におけるエピアロプレグナノロン
|
US20020198174A1
(en)
|
2001-05-07 |
2002-12-26 |
Allergan Sales, Inc. |
Disinfecting and solubilizing steroid compositions
|
US6376531B1
(en)
|
1998-11-13 |
2002-04-23 |
Rupert Charles Bell |
Method of treatment using deuterium compounds
|
US20030236236A1
(en)
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
ATE234299T1
(de)
|
1999-12-03 |
2003-03-15 |
Pfizer Prod Inc |
Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
|
US6442887B2
(en)
|
2000-02-25 |
2002-09-03 |
Robert L. Sanquist |
Live bait keeper
|
US6589549B2
(en)
|
2000-04-27 |
2003-07-08 |
Macromed, Incorporated |
Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
|
US6613308B2
(en)
|
2000-09-19 |
2003-09-02 |
Advanced Inhalation Research, Inc. |
Pulmonary delivery in treating disorders of the central nervous system
|
US20020072509A1
(en)
*
|
2000-10-11 |
2002-06-13 |
Stein Donald Gerald |
Methods for the treatment of a traumatic central nervous system injury
|
EP1216713A1
(en)
|
2000-12-20 |
2002-06-26 |
Schering Aktiengesellschaft |
Compositions of estrogen-cyclodextrin complexes
|
GR1003861B
(el)
|
2000-12-29 |
2002-04-11 |
|
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
|
EP1360310A2
(en)
|
2001-02-13 |
2003-11-12 |
University Of Florida |
A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
|
US20030055026A1
(en)
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
WO2002094244A2
(en)
|
2001-05-24 |
2002-11-28 |
Alexza Molecular Delivery Corporation |
Delivery of benzodiazepines through an inhalation route
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
US6737043B2
(en)
|
2001-05-24 |
2004-05-18 |
Alexza Molecula Delivery Corporation |
Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
|
JP2003063965A
(ja)
*
|
2001-06-13 |
2003-03-05 |
Otsuka Pharmaceut Factory Inc |
注射用シロスタゾール水性製剤
|
US7122593B2
(en)
|
2002-01-14 |
2006-10-17 |
Ansell Healthcare Products Llc |
Magnetically detectable latex articles
|
US7550155B2
(en)
|
2002-07-29 |
2009-06-23 |
Transform Pharmaceuticals Inc. |
Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
|
EP1539183A4
(en)
|
2002-08-28 |
2007-04-25 |
Hollis Eden Pharmaceuticals |
THERAPEUTIC TREATMENT METHODS
|
US9339508B2
(en)
|
2003-01-17 |
2016-05-17 |
Mapreg |
Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury
|
EP1626980A4
(en)
|
2003-05-29 |
2007-07-04 |
Univ Washington |
NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS
|
US7816074B2
(en)
|
2003-07-31 |
2010-10-19 |
The Research Foundation Of State University Of New York |
α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism
|
GB0321607D0
(en)
|
2003-09-15 |
2003-10-15 |
Vectura Ltd |
Manufacture of pharmaceutical compositions
|
AU2004308935A1
(en)
*
|
2003-12-22 |
2005-07-14 |
Schering Corporation |
Pharmaceutical compositions
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
ATE497787T1
(de)
|
2004-03-12 |
2011-02-15 |
Cipla Ltd |
Sterilisationsprozess für steroide
|
US20090118248A1
(en)
|
2004-04-23 |
2009-05-07 |
Euro-Celtique S.A. |
3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
|
ITMI20041763A1
(it)
|
2004-09-16 |
2004-12-16 |
Altergon Sa |
Nuove formulazioni iniettabili contenenti progesterone
|
WO2006034196A1
(en)
|
2004-09-17 |
2006-03-30 |
Lifelike Biomatic Inc. |
Compositions for enhancing memory and methods therefor
|
WO2006037016A2
(en)
|
2004-09-27 |
2006-04-06 |
The Regents Of The University Of California |
Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
US8557861B2
(en)
|
2004-09-28 |
2013-10-15 |
Mast Therapeutics, Inc. |
Low oil emulsion compositions for delivering taxoids and other insoluble drugs
|
CA2582231A1
(en)
|
2004-09-29 |
2006-10-19 |
Hollis-Eden Pharmaceuticals, Inc. |
Steroid analogs and uses
|
HUE027850T2
(en)
|
2004-12-07 |
2016-11-28 |
Onyx Therapeutics Inc |
Preparation for proteasome inhibition
|
EP2353590A1
(en)
|
2005-02-15 |
2011-08-10 |
Elan Pharma International Limited |
Aerosol and injectable formulations of nanoparticulate benzodiazepine
|
JP5295755B2
(ja)
*
|
2005-03-24 |
2013-09-18 |
エモリー ユニバーシティー |
プロゲステロンによる外傷性脳損傷の治療のための投薬レジメン
|
EP1868593A2
(en)
|
2005-04-07 |
2007-12-26 |
Hythiam, Inc. |
Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
|
US20110319386A1
(en)
|
2005-08-26 |
2011-12-29 |
Braincells Inc. |
Neurogenesis by muscarinic receptor modulation
|
KR100784860B1
(ko)
|
2005-10-31 |
2007-12-14 |
삼성전자주식회사 |
비휘발성 메모리 장치 및 그 제조 방법
|
AU2006318349B2
(en)
|
2005-11-28 |
2010-08-19 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the making and use thereof
|
TWI376239B
(en)
|
2006-02-01 |
2012-11-11 |
Andrew Xian Chen |
Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
|
US20070287931A1
(en)
|
2006-02-14 |
2007-12-13 |
Dilorenzo Daniel J |
Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
|
WO2008030651A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20090239942A1
(en)
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
US20090203658A1
(en)
|
2007-01-08 |
2009-08-13 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
US20090074677A1
(en)
|
2007-01-08 |
2009-03-19 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
US7813811B2
(en)
|
2007-02-08 |
2010-10-12 |
Neuropace, Inc. |
Refillable reservoir lead systems
|
EP2139485B1
(en)
|
2007-04-11 |
2012-10-17 |
BioMarin Pharmaceutical Inc. |
Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
US8969329B2
(en)
*
|
2007-06-11 |
2015-03-03 |
University Of Southern California |
Allopregnanolone in a method for enhancing neurological function
|
ES2589139T3
(es)
|
2007-06-15 |
2016-11-10 |
Research Triangle Institute |
Esteroides de androstano y pregnano con potentes propiedades de modulación alostérica del complejo receptor GABA/ionóforo cloruro
|
GB0711948D0
(en)
|
2007-06-20 |
2007-08-01 |
Bionature E A Ltd |
Neurosteriod compounds
|
EP2175886A1
(en)
|
2007-06-28 |
2010-04-21 |
CNSBio Pty Ltd |
Combination methods and compositions for treatment of neuropathic pain
|
US20100297181A1
(en)
|
2007-12-26 |
2010-11-25 |
Eisai R&D Management Co., Ltd. |
AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
|
BRPI0821970A2
(pt)
|
2008-01-03 |
2015-06-23 |
Biomarin Pharm Inc |
Análogos de pterina para tratamento de condição responsiva a bh4
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
US8729070B2
(en)
|
2008-02-20 |
2014-05-20 |
Targia Pharmaceuticals |
CNS pharmaceutical compositions and methods of use
|
DE102008015366A1
(de)
|
2008-03-20 |
2009-09-24 |
Merck Patent Gmbh |
Lyophilisierte Nanoemulsion
|
CZ2008434A3
(cs)
|
2008-07-10 |
2009-12-09 |
Ústav organické chemie a biochemie Akademie ved CR, v. v. i. |
Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
|
CN106243100B
(zh)
|
2008-10-10 |
2019-04-09 |
Vm生物医药公司 |
治疗酒精使用障碍,疼痛和其他疾病的药物组合与方法
|
CN102300566A
(zh)
|
2008-11-30 |
2011-12-28 |
O·扎查尔 |
血管收缩剂的皮肤应用
|
US20110306579A1
(en)
*
|
2009-01-30 |
2011-12-15 |
Emory University |
Methods of neuroprotection using neuroprotective steroids and a vitamin d
|
WO2010107922A1
(en)
|
2009-03-17 |
2010-09-23 |
Duke University |
Neuroactive steroid compositions and methods of use for lowering cholesterol
|
WO2011079047A1
(en)
|
2009-12-23 |
2011-06-30 |
Drugtech Corporation |
Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
|
WO2011088503A1
(en)
*
|
2010-01-21 |
2011-07-28 |
Goodchild Investments Pty Ltd |
Anaesthetic formulation
|
RU2576506C2
(ru)
|
2010-11-03 |
2016-03-10 |
Санофи-Авентис Дойчланд Гмбх |
Игольчатая канюля, содержащая лекарственный препарат
|
WO2012075286A2
(en)
|
2010-12-01 |
2012-06-07 |
The Regents Of The University Of California |
Intrapulmonary benzodiazepine for the treatment and prevention of seizures
|
CZ303443B6
(cs)
|
2011-02-15 |
2012-09-12 |
Ústav organické chemie a biochemie Akademie ved CR, v.v.i. |
Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
|
WO2012116290A2
(en)
|
2011-02-25 |
2012-08-30 |
Washington University |
Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
FR2973031B1
(fr)
|
2011-03-23 |
2013-11-29 |
Univ Strasbourg |
Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
|
US9084797B2
(en)
|
2011-05-23 |
2015-07-21 |
Besins Healthcare Luxembourg Sarl |
Progesterone treatment for improving sleep quality
|
EP2727473A4
(en)
|
2011-06-28 |
2015-05-06 |
Vivozon Inc |
COMBINATION OF EFFICIENT SUBSTANCES WITH SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF
|
JP2014521662A
(ja)
|
2011-07-29 |
2014-08-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
GABAA受容体のモジュレーターとしての新規な17β−ヘテロアリール置換ステロイド
|
CN113956315A
(zh)
|
2011-09-08 |
2022-01-21 |
萨奇治疗股份有限公司 |
神经活性类固醇、组合物、及其用途
|
WO2013043985A1
(en)
|
2011-09-23 |
2013-03-28 |
The Regents Of The University Of California |
Edible oils to enhance delivery of orally administered steroids
|
ES2738526T3
(es)
|
2011-10-14 |
2020-01-23 |
Sage Therapeutics Inc |
Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
|
DK2785352T3
(da)
|
2011-11-29 |
2020-05-25 |
Jurox Pty Ltd |
Stabile injicerbare farmaceutiske sammensætninger omfattende 2-hydroxypropyl-beta-cyclodextrin og alfaxalon
|
RU2014121785A
(ru)
|
2011-11-29 |
2016-01-27 |
Амино Ап Кемикал Ко., Лтд. |
Композиция, содержащая виценин-2, обладающая благоприятным воздействием на неврологическую или когнитивную функцию
|
PL2806877T3
(pl)
|
2012-01-23 |
2020-06-01 |
Sage Therapeutics, Inc. |
Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
|
US20150175651A1
(en)
|
2012-06-15 |
2015-06-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
WO2014028398A2
(en)
|
2012-08-13 |
2014-02-20 |
The Regents Of The University Of California |
Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
|
EP3957309A1
(en)
|
2012-08-21 |
2022-02-23 |
Sage Therapeutics, Inc. |
Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin
|
US9765110B2
(en)
|
2012-10-08 |
2017-09-19 |
Washington University |
Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
WO2014071449A1
(en)
|
2012-11-09 |
2014-05-15 |
Goodchild Investments Pty Ltd |
Neuroactive steroids and their use to facilitate neuroprotection
|
JP2016501876A
(ja)
|
2012-11-30 |
2016-01-21 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ステロイドの抗痙攣活性
|
RU2663665C2
(ru)
|
2012-12-18 |
2018-08-08 |
Вашингтон Юниверсити |
Нейроактивные 19-алкокси-17-замещенные стероиды и способы лечения с их применением
|
WO2014108808A2
(en)
|
2013-01-09 |
2014-07-17 |
Henry James Lorne |
Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
|
US20160068563A1
(en)
|
2013-04-17 |
2016-03-10 |
Boyd L. Harrison |
19-nor neuroactive steroids and methods of use thereof
|
SG11201508550XA
(en)
|
2013-04-17 |
2015-11-27 |
Sage Therapeutics Inc |
19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
|
CA2909546C
(en)
|
2013-04-17 |
2019-01-22 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids and methods of use thereof
|
WO2015195962A1
(en)
|
2014-06-18 |
2015-12-23 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
AU2016214996B2
(en)
|
2015-02-06 |
2021-03-04 |
Marinus Pharmaceuticals, Inc. |
Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
|
GB2541015A
(en)
|
2015-08-06 |
2017-02-08 |
Ge Oil & Gas Uk Ltd |
Subsea flying lead
|
US20180235916A1
(en)
|
2015-10-14 |
2018-08-23 |
The Regents Of The University Of California |
Enhancing beta cell replication and/or survival
|
MA43815A
(fr)
|
2016-03-08 |
2021-04-07 |
Sage Therapeutics Inc |
Stéroïdes neuroactifs, compositions, et leurs utilisations
|
US20180050005A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
|
US20180050107A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Neurosteroid compositions and methods of use thereof
|
CN110072523A
(zh)
|
2016-09-07 |
2019-07-30 |
格利亚有限责任公司 |
通过脑神经的药理皮肤激活来治疗与神经退行性病症相关的症状
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
WO2018169798A1
(en)
|
2017-03-11 |
2018-09-20 |
The Regents Of The University Of California |
Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers
|
KR20190137839A
(ko)
|
2017-04-18 |
2019-12-11 |
마리누스 파마슈티컬스 인코포레이티드 |
지속 방출 주사용 뉴로스테로이드 제제
|
US11752115B2
(en)
|
2017-06-21 |
2023-09-12 |
The Board Of Trustees Of The University Of Illinois |
PPAR-alpha agonist treatment of neuropsychiatric disorders
|
EP3641779B1
(en)
|
2017-06-23 |
2024-02-28 |
The Board of Trustees of the University of Illinois |
Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
|
EP3642206A4
(en)
|
2017-06-23 |
2021-04-07 |
The Regents of The University of California |
IMPROVING THE CAPACITY OF GABA TO MODULATE IMMUNE RESPONSES
|
US20200276209A1
(en)
|
2017-09-11 |
2020-09-03 |
Sage Therapeutics, Inc. |
Methods of treating epilepsy or status epilepticus
|
CA3075872A1
(en)
|
2017-09-14 |
2019-03-21 |
Sage Therapeutics, Inc. |
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|
SG11202004329TA
(en)
|
2017-11-10 |
2020-06-29 |
Marinus Pharmaceuticals Inc |
Ganaxolone for use in treating genetic epileptic disoders
|
WO2019113494A1
(en)
|
2017-12-08 |
2019-06-13 |
Sage Therapeutics, Inc. |
Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
|
AU2018388408B2
(en)
|
2017-12-22 |
2023-12-21 |
Sage Therapeutics, Inc. |
Compositions and methods for treating CNS disorders
|
CA3086189A1
(en)
|
2017-12-22 |
2019-06-27 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
WO2019140272A1
(en)
|
2018-01-12 |
2019-07-18 |
Sage Therapeutics, Inc. |
Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
|
CN112823164A
(zh)
|
2018-05-04 |
2021-05-18 |
阿克罗斯制药公司 |
神经甾体衍生物和其用途
|
CN117959309A
(zh)
|
2018-06-12 |
2024-05-03 |
萨奇治疗股份有限公司 |
19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
|
EP3864022B1
(en)
|
2018-10-12 |
2023-09-20 |
Sage Therapeutics, Inc. |
Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
|
JP2022505146A
(ja)
|
2018-10-19 |
2022-01-14 |
セージ セラピューティクス, インコーポレイテッド |
9(11)-不飽和神経刺激性ステロイド及びそれらの使用方法
|
MA54594A
(fr)
|
2018-12-05 |
2022-04-06 |
Sage Therapeutics Inc |
Stéroïdes neuroactifs et leurs procédés d'utilisation
|
WO2020132504A1
(en)
|
2018-12-21 |
2020-06-25 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
|
TW202110824A
(zh)
|
2019-05-24 |
2021-03-16 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|
MX2021014515A
(es)
|
2019-05-31 |
2022-03-22 |
Sage Therapeutics Inc |
Esteroides neuroactivos y composiciones de estos.
|
AU2020395246A1
(en)
|
2019-12-05 |
2022-06-16 |
Sage Therapeutics, Inc. |
A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof
|
IL296371A
(en)
|
2020-03-18 |
2022-11-01 |
Sage Therapeutics Inc |
Neuroactive steroids and methods of using them
|
CA3176854A1
(en)
|
2020-03-25 |
2021-09-30 |
Sage Therapeutics, Inc. |
Use of agents for treatment of respiratory conditions
|
BR112023000990A2
(pt)
|
2020-07-20 |
2023-03-28 |
Sage Therapeutics Inc |
Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas
|